BioSpace News Archive

Immunitas Therapeutics announced it will present preclinical data supporting the combination potential of IMT-009, its first-in-class anti-CD161 antibody under clinical evaluation for use in solid tumor and hematologic malignancies, with anti-PD1 immunotherapy at the American Association for Cancer Research Annual Meeting, held April 5-10 in San Diego, California.

DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.

AffyImmune Therapeutics, Inc. announced that it will present an abstract in a poster session at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10, 2024, in San Diego, California.

Prelude Therapeutics Incorporated announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024, taking place from April 5 to 10, 2024.

Pyxis Oncology, Inc. (Nasdaq: PYXS) announced today that the company will present new preclinical data in four posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, held from April 5 to 10, 2024.

Kronos Bio, Inc. (Nasdaq: KRON) today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.

Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that one abstract has been selected for an oral minisymposium and seven abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.

Foghorn® Therapeutics Inc. announced that preclinical data for its pipeline programs, including the first presentation of preclinical data for FHD-909, a potential first-in-class BRM selective inhibitor will be presented at the 2024 American Association for Cancer Research Annual Meeting being held April 5-10, 2024 in San Diego, California.

Avacta Group plc announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024.

Zymeworks Inc. announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research Annual Meeting taking place at the San Diego Convention Center in San Diego, CA from April 5-10, 2024.